7 / 13
Advanced Stem Cell 2018
Journal of Stem Cell Biology and Transplantation
ISSN: 2575-7725
Page 42
December 03-04, 2018
Valencia, Spain
15
th
Edition of EuroSciCon Conference on
Advanced Stem Cell &
Regenerative Medicine
T
he large-scale clinical expansion of MSCs to therapeutically
relevant doses is a challenge to those in the cell therapy space
phase. In addition, identifying donors that produce cells capable
of withstanding the effect of extended passaging can be difficult.
In order to assess whether cells are maintaining their activity
and potency, we have focused developing assays around a novel
cell-surface stromal cell marker, CD362/Syndecan-2 (SDC2). The
heparan sulfate proteoglycan syndecans are transmembrane
proteins involved in multiple physiological processes, including
cell-matrix adhesion and inflammation. We found that the protein
expression of SDC2 in umbilical cord-derived MSCs (ucMSCs) is
lost with serial passaging and consecutive bioreactor expansions
and this effect correlates with loss of IDO-1 activity/expression
and reducedsuppressionofCD4+T-cell proliferation. Furthermore,
inflammation-induced loss of SDC2 by TNF-α or IL-1β promotes
apoptosis, and increased CD54/ICAM-1 and MHC II expression in
these cells and this phenotype is mirrored with adenoviral knock-
down or siRNA directed against SDC2. This indicates that loss
of stromal cell SDC2 has a negative impact on the potency of
ucMSCs. Furthermore, certain donors with higher IFNƴ-stimulated
indoleamine 2, 3-dioxygenase IDO-1 and SDC2 expression,
continue to express high levels through passaging and perform
better in-vitro than those with lower starting expression, allowing
the potential pre-selection of donors from as early a passage as
P1-P2.
Laura.deedigan@orbsentherapeutics.comSyndecan-2: more than just a stromal cell marker
Laura Deedigan
1
, P Loftus
1,2
, L Barkely
2
, L O Flynn
1
and
S Elliman
1
1
Orbsen Therapeutics - NUI, Republic of Ireland
2
Lambe Institute for Translational Research - NUI, Republic of Ireland
J Stem Cell Biol Transplant 2018, Volume 2
DOI: 10.21767/2575-7725-C1-003